EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 3.0

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment

Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D Parikh, Ghassan K Abou-Alfa, Amit G Singal, Ju Dong Yang

Clinical and Molecular Hepatology · 28.02.2025 · 31 (Suppl) · S228-S254

DOI: 10.3350/cmh.2024.0824 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 28.02.2025. Verfasst von Soo Young Hwang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Maryland Medical Center, Midtown Campus, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms. Die Arbeit wurde bisher 358-mal zitiert (Crossref) und nennt 228 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NCI NIH HHS, Servier, Astra Zeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality. HCC due to chronic hepatitis B virus (HBV) or C virus (HCV) infection has decreased due to universal vaccination for HBV and effective antiviral therapy for both HBV and HCV, but HCC related to metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease is increasing. Biannual liver ultrasonography and serum α-fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.g., cirrhosis, chronic HBV). Alternative surveillance tools such as blood-based biomarker panels and abbreviated magnetic resonance imaging (MRI) are being investigated. Multiphasic computed tomography or MRI is the standard for HCC diagnosis, but histological confirmation should be considered, especially when inconclusive findings are seen on cross-sectional imaging. Staging and treatment decisions are complex and should be made in multidisciplinary settings, incorporating multiple factors including tumor burden, degree of liver dysfunction, patient performance status, available expertise, and patient preferences. Early-stage HCC is best treated with curative options such as resection, ablation, or transplantation. For intermediate-stage disease, locoregional therapies are primarily recommended although systemic therapies may be preferred for patients with large intrahepatic tumor burden. In advanced-stage disease, immune checkpoint inhibitor-based therapy is the preferred treatment regimen. In this review article, we discuss the recent global epidemiology, risk factors, and HCC care continuum encompassing surveillance, diagnosis, staging, and treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsHumansMagnetic Resonance Imagingalpha-FetoproteinsNeoplasm Staging

Stichwörter der Autor:innen

Hepatocellular carcinomaLiver cirrhosisLiver diseasesLiver neoplasms

Substanzen

alpha-Fetoproteins

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Maryland Medical Center, Midtown Campus, Baltimore, Maryland, USA.
  • Department of Internal Medicine, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
  • Dumont-UCLA Transplant and Liver Cancer Centers, Department of Surgery, David Geffen School of Medicine at UCLA, Los Angeles, California, USA.
  • Division of Gastroenterology, Department of Medicine, University of California, San Francisco, California, USA.
  • Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, Michigan, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.

Förderung

  • NCI NIH HHS
  • Servier
  • Astra Zeneca
  • QED
  • NIMHD NIH HHS
  • Yiviva
  • Arcus
  • Agenus

Zitieren

APA

Hwang, S. Y., Danpanichkul, P., Agopian, V., Mehta, N., Parikh, N. D., Abou-Alfa, G. K., Singal, A. G., & Yang, J. D. (2025). Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clinical and Molecular Hepatology, 31(Suppl), S228-S254. https://doi.org/10.3350/cmh.2024.0824

Vancouver

Hwang SY, Danpanichkul P, Agopian V, Mehta N, Parikh ND, Abou-Alfa GK, et al. Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment. Clinical and Molecular Hepatology. 2025;31(Suppl):S228-S254. doi:10.3350/cmh.2024.0824

BibTeX
@article{Hwang2025,
  author = {Hwang, Soo Young and Danpanichkul, Pojsakorn and Agopian, Vatche and Mehta, Neil and Parikh, Neehar D and Abou-Alfa, Ghassan K and Singal, Amit G and Yang, Ju Dong},
  title = {Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment},
  journal = {Clinical and Molecular Hepatology},
  year = {2025},
  volume = {31},
  number = {Suppl},
  pages = {S228--S254},
  doi = {10.3350/cmh.2024.0824}
}
Kostenlos starten →